Evaluation of four prognostic indices in follicular lymphoma treated in first line with immunochemotherapy

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Rodríguez-Sevilla, Juan José
• dc.contributor.author Fernández Rodríguez, M. Concepción
• dc.contributor.author Bento, Leyre
• dc.contributor.author Díez-Feijóo, Ramón
• dc.contributor.author Felipe Pinzon, Sergio
• dc.contributor.author Gibert Fernandez, Joan, 1988-
• dc.contributor.author Fernández-Ibarrondo, Lierni
• dc.contributor.author Lafuente, Marta
• dc.contributor.author Ferrer Del Alamo, Ana
• dc.contributor.author Sánchez González, Blanca
• dc.contributor.author Gimeno Vázquez, Eva
• dc.contributor.author Sainz, Juan
• dc.contributor.author Ramos-Asensio, Rafael
• dc.contributor.author García, Juan Fernando
• dc.contributor.author Colomo Saperas, Luis Alberto
• dc.contributor.author Bellosillo Paricio, Beatriz
• dc.contributor.author Gutierrez, Antonio
• dc.contributor.author Salar Silvestre, Antonio
• dc.date.accessioned 2023-01-17T08:02:44Z
• dc.date.available 2023-01-17T08:02:44Z
• dc.date.issued 2022
• dc.description [AHEAD] Data de publicació electrónica: 19-10-2022
• dc.description.abstract Several clinical risk models have been proposed to predict outcome in follicular lymphoma (FL). The development of Next Generation Sequencing (NGS) technologies has allowed the integration of somatic gene mutations in clinical scores to build genotyped-based risk models, such as m7-FLIPI. We explored four clinical or clinicogenetic risk models in patients with symptomatic FL who received frontline immunochemotherapy. Out of 191 patients with FL grade 1-3a, 109 were successfully genotyped. Treatment consisted on rituximab (R) plus CVP/CHOP (72.5%) or R-bendamustine (R-B) (27.5%). The proportion of cases classified as high-risk in FLIPI, FLIPI-2, PRIMA-PI or m7-FLIPI were 39.3%, 14%, 30.3%, 22%, respectively. No case with low-intermediate FLIPI was upgraded in m7-FLIPI, but 18 out of 42 higher-risk patients in FLIPI were downgraded to low-risk m7-FLIPI. Sensitivity and specificity for the prediction of POD24 was highest for FLIPI. The discrimination for progression free survival (PFS) and overall survival (OS) was best for FLIPI (c-index: 0.644 and 0.727, respectively). When analyzed only R-B patients, m7-FLIPI had higher discrimination for PFS and OS. Thus, FLIPI remains as the clinical risk score with higher discrimination in advanced FL patients treated with immunochemotherapy, but the performance of m7-FLIPI should be further investigated in patients treated with R-B.
• dc.format.mimetype application/pdf
• dc.identifier.citation Rodríguez-Sevilla JJ, Fernández-Rodríguez C, Bento L, Diez-Feijóo R, Pinzon SF, Gibert J, et al. Evaluation of four prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. Blood Adv. 2022 Oct 19: bloodadvances. 2022007949. DOI: 10.1182/bloodadvances.2022007949
• dc.identifier.doi http://dx.doi.org/10.1182/bloodadvances.2022007949
• dc.identifier.issn 2473-9529
• dc.identifier.uri http://hdl.handle.net/10230/55299
• dc.language.iso eng
• dc.publisher American Society of Hematology
• dc.rights Copyright ©2023 by American Society of Hematology
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.other Limfomes -- Tractament
• dc.subject.other Immunoteràpia
• dc.subject.other Genètica
• dc.title Evaluation of four prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion